Publications

Tigecycline activity tested against infrequently recovered clinical species of non-enteric Gram-negative bacilli, Lead author: Mendes RE, presented at 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10 – 13, 2010, Vienna, Austria

CEM-101, a novel fluoroketolide, tested against European clinical isolates from 2009 (first-year surveillance results), Lead author: Castanheira M, presented at 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10 – 13, 2010, Vienna, Austria

Expanded studies of CEM-101, a novel fluoroketolide, tested against invasive isolates of N. meningitidis,including fluoroquinolone-non-susceptible resistant strains, Lead author: Biedenbach DJ, presented at 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10 – 13, 2010, Vienna, Austria

Antimicrobial activity of the investigational pleuromutilin compound BC-3781 against Gram-positive organisms commonly associated with cutaneous infections, Lead author: Sader HS, presented at 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10 – 13, 2010, Vienna, Austria

Activity of BC-3205 when tested against Gram-positive organisms responsible from skin and skin structure infections, Lead author: Sader HS, presented at 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10 – 13, 2010, Vienna, Austria

Disc diffusion and MIC quality control ranges for BC-3205, a novel pleuromutilin class antimicrobial, Lead author: Ross JE, presented at 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10 – 13, 2010, Vienna, Austria

Correlation of in vitro susceptibility testing results for an investigational pleuromutilin (BC-3781) using MIC and disc diffusion methods against Gram-positive pathogens, Lead author: Biedenbach DJ, presented at 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10 – 13, 2010, Vienna, Austria

Correlations of broth microdilution MIC and disc diffusion results for an investigational agent, BC-3205 among potentially indicated species, Lead author: Biedenbach DJ, presented at 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10 – 13, 2010, Vienna, Austria

CEM-102 (fusidic acid) in vitro activity and evaluation of molecular resistance mechanisms among European Gram-positive isolates, 2008-2009, Lead author: Castanheira M, presented at 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10 – 13, 2010, Vienna, Austria

Antimicrobial activity of ceftaroline tested against Staphylococcus aureus from the United States and Europe, 2008-2009, Lead author: Sader HS, presented at 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10 – 13, 2010, Vienna, Austria

Antimicrobial spectrum of activity of telavancin and comparator agents tested against methicillin-resistant Staphylococcus aureus recovered from United States and European hospitals over a 3-year sampling period (2007-2009), Lead author: Mendes RE, presented at 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10 – 13, 2010, Vienna, Austria

Activity of ceftaroline against selected clinical isolates of Staphylococcus aureus from the Canadian Bacterial Sentinel Network, Lead author: Farrell DJ, presented at 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10 – 13, 2010, Vienna, Austria

Spectrum of activity of oritavancin and comparator agents tested against subsets of vancomycin-resistant enterococci from the United States and Europe, Lead author: Mendes RE, presented at 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10 – 13, 2010, Vienna, Austria

Differences between adult and paediatric serotypes and activity of ceftaroline for recent US isolates of Streptococcus pneumoniae, Lead author: Jacobs, presented at 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10 – 13, 2010, Vienna, Austria

16S rRNA methylase containing Enterobacteriaceae in the SENTRY Asia-Pacific region frequently harbour plasmid-mediated quinolone resistance and CTX-M types, Lead author: Bell JM, presented at 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10 – 13, 2010, Vienna, Austria

Initial MIC and disc diffusion quality control ranges for BC-3781 using the CLSI Multi-Laboratory M23-A3 study design, Lead author: Ross JE, presented at 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10 – 13, 2010, Vienna, Austria

Five-Year Trend of Antimicrobial Susceptibility Rates and Daptomycin Activity among Staphylococcus aureus Isolates Collected in Latin American Medical Centers (2005-2009), Lead author: Sader HS, presented at 14th annual International Congress on Infectious Diseases (ICID), March 9 – 12, 2010, Miami, FL

Multicenter evaluation of tigecycline activity in Latin America: Report from the SENTRY antimicrobial surveillance program (2009), Lead author: Farrell DJ, presented at 14th annual International Congress on Infectious Diseases (ICID), March 9 – 12, 2010, Miami, FL

Daptomycin activity and spectrum when tested against contemporary (2009) Gram-positive strains collected in Latin American medical centers, Lead author: Sader HS, presented at 14th annual International Congress on Infectious Diseases (ICID), March 9 – 12, 2010, Miami, FL

Daptomycin activity against enterococci from Latin American medical centers, including Vancomycin-resistant strains (2005-2009), Lead author: Sader HS, presented at 14th annual International Congress on Infectious Diseases (ICID), March 9 – 12, 2010, Miami, FL

Tigecycline activity against multidrug-resistant enterobacteriaceae isolated in the Latin American (LA) Region, Lead author: Sader HS, presented at 14th annual International Congress on Infectious Diseases (ICID), March 9 – 12, 2010, Miami, FL

Activity of tigecycline and comparators tested against Streptococcus pneumoniae isolated from patients with community-acquired respiratory tract infection (CARTI) in Latin American medical centers (2005-2009), Lead author: Sader HS, presented at 14th annual International Congress on Infectious Diseases (ICID), March 9 – 12, 2010, Miami, FL

Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. by Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, Sorgel F, Jones RN, Drusano GL, Bertino Jr. JS published in Diagn. Microbiol. Infect. Dis. 2010; 68 (3): 251-258

Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: Report from the SENTRY Antimicrobial Surveillance Program (2008-2009). by Pfaller MA, Castanheira M, Messer SA, Moet GJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2010; 68 (3): 278-283

Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: Report from the SENTRY Antimicrobial Surveillance Program (1998-2009). by Jones RN, Sader HS, Moet GJ, Farrell DJ published in Diagn. Microbiol. Infect. Dis. 2010; 68 (3): 334-336

Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009). by Mendes RE, Farrell DJ, Sader HS, Jones RN published in Diagn. Microbiol. Infect. Dis. 2010; 68 (3): 307-311

Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. by Jones RN, Biedenbach DJ, Roblin PM, Kohlhoff SA and Hammerschlag MR published in Antimicrob. Agents Chemother. 2010; 54 (10): 4518-4519

Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008) by Mendes RE, Sader HS and Jones RN published in Int. J. Antimicrob. Agents. 2010; 36 (4): 374-379

Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp. and Aspergillus spp.: Results from the Global SENTRY Antimicrobial Surveillance Program (2008). by Messer SA, Jones RN, Moet GJ, Kirby JT and Castanheira M published in J. Clin. Microbiol. 2010; 48 (8): 2984-2987

Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. by Putnam SD, Sader HS, Moet GJ, Mendes RE and Jones RN published in Diagn. Microbiol. Infect. Dis. 2010; 67 (4): 359-368

Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. by Jones RN, Jacobs MR and Sader HS published in Int. J. Antimicrob. Agents 2010; 36 (3): 197-204

Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008). by Castanheira M, Watters AA, Mendes RE, Farrell DJ, Jones RN published in J. Antimicrob. Chemother. 2010; 65 (7): 1353-1358

Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. by Johnson JR, Johnston B, Clabots C, Kushkowski MA and Castanheira M published in Clin. Infect. Dis. 2010; 51 (3): 286-294

Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. by Jones RN published in Clin. Infect. Dis. 2010; 51 (Suppl 1): S81-S87

Escherichia coli resistant to quinolones at a comprehensive cancer center. by Mihu CN, Rhomberg PR, Jones RN, Coyle E, Prince RA and Rolston KV published in Diagn. Microbiol. Infect. Dis. 2010; 67: 266-269

Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres. by Sader HS, Farrell DJ and Jones RN published in Int. J. Antimicrob. Agents 2010; 36 (1): 28-32

Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. by Farrell DJ, Sader HS, Jones RN published in Antimicrob. Agents Chemother. 2010; 54 (6): 2735

In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp. by Biedenbach DJ, Ross JE, Putnam SD and Jones RN published in Antimicrob. Agents Chemother. 2010; 54 (5): 2273-2275

CEM-101 activity against Gram-positive organisms. by Woosley LN, Castanheira M, Jones RN published in Antimicrob. Agents Chemother. 2010; 54 (5): 2182-2187

CEM-101, a novel fluoroketolide: Antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. by Putnam SD, Castanheira M, Moet GJ, Farrell DJ, Jones RN published in Diagn. Microbiol. Infect. Dis. 2010; 66 (4): 393-401

MIC quality control guidelines and disk diffusion test optimization for CEM-101, a novel fluoroketolide. by Jones RN, Ross JE, Rhomberg PR published in J. Clin. Microbiol. 2010; 48 (4): 1470-1473

Performance of fusidic acid (CEM-102) susceptibility testing reagents: Broth microdilution, disk diffusion, and Etest methods as applied to Staphylococcus aureus. by Jones RN, Castanheira M, Rhomberg PR, Woosley LN and Pfaller MA published in J. Clin. Microbiol. 2010; 48: 972-976

Sustained antimicrobial activity of tigeycline against methicillin-resistant Staphylococcus aureus (MRSA) from United States medical centers from 2004 through 2008. by Putnam SD, Sader HS, Farrell DJ and Jones RN published in J. Chemother. 2010; 22 (1): 13-16

Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102). by Biedenbach DJ, Rhomberg PR, Mendes RE and Jones RN published in Diagn. Microbiol. Infect. Dis. 2010; 66 (3): 301-307

Clonal dissemination of Klebsiella pneumoniae carbapenemase KPC in Long Beach, California. by Le J, Castanheira M, Burgess DS, McKee B, Iqbal R, Jones RN published in J. Clin. Microbiol. 2010; 48 (2): 623-625

Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 µg/mL isolated in the United States and European hospitals (2006-2008). by Sader HS, Becker HK, Moet GJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2010; 66 (3): 329-331

Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada by Pfaller MA, Castanheira M, Sader HS, Jones RN published in Int. J. Antimicrob. Agents 2010; 35 (3): 282-287

Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from Phase IV clinical trial for linezolid. by Mendes RE, Sader HS, Deshpande LM, Diep BA, Chamers HF, Jones RN published in J. Clin. Microbiol. 2010; 48 (2): 568-574

Wild-type MIC distributions and epidemiologic cutoff values for the Echinocandins and Candida spp. by Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Jones RN, Turnidge J and Diekema D published in J. Clin. Microbiol. 2010; 48 (1):52-56

Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States by Jacobs MR, Good CE, Windau AR, Bajaksouzian S, Biek D, Critchley I, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2010; 54 (6): 2716-2719